A Phase I/II Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma.

The trial is divided into two parts. PART 1 is a dose escalation study of the ZG005 combined with Etoposide and Cisplatin, primarily assessing the tolerability and safety of this combined treatment. PART 2 is a dose expansion study, further evaluating the preliminary efficacy and safety of this combined treatment.

开始日期2024-08-01

申办/合作机构

苏州泽璟生物制药股份有限公司

NCT06377540 / Not yet recruiting临床2期IIT

MT2022-60: A Phase II Study of Pembrolizumab+ BEAM Conditioning Regimen Before Autologous Stem Cell Transplant (ASCT) Followed by Pembrolizumab Maintenance in Patients of Relapsed or Refractory Classic Hodgkin Lymphoma

This is a Phase 2 single arm study to evaluate efficacy and safety of Pembrolizumab before with BEAM ASCT followed by Pembrolizumab maintenance for 1 year. Patients will receive 200 mg Pembrolizumab Q3week starting at day - 28 before stem cell transplant until 1 year after autologous stem cell transplant.

开始日期2024-08-01

申办/合作机构

University of Minnesota Masonic Cancer Center

NCT06110572 / Recruiting临床1/2期IIT

(TESSERACT): Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation (TBI)

This phase I/II trial studies the side effects, safety, and effectiveness of low dose radiation to the entire body (total body irradiation [TBI]) and higher dose radiation to known areas of cancer (hypofractionated radiation therapy [H-RT]) combined with atezolizumab and chemotherapy (carboplatin & etoposide) in treating patients with small cell lung cancer that has spread to disease sites outside of the lung (extensive stage). Extensive stage disease has historically been treated with chemotherapy alone with consideration of chest (thoracic) radiation therapy for those with response to chemotherapy, as well as consideration of preventative radiation therapy to the head (prophylactic cranial irradiation). Emerging evidence supports the synergistic interactions between immunotherapy and radiation therapy. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair and may kill tumor cells. Combining TBI and H-RT with atezolizumab and chemotherapy may improve response to treatment.

开始日期2024-07-31

申办/合作机构

The Vanderbilt-Ingram Cancer Center

[+1]

100 项与依托泊苷相关的临床结果

登录后查看更多信息

100 项与依托泊苷相关的转化医学

登录后查看更多信息

100 项与依托泊苷相关的专利（医药）

登录后查看更多信息

23,082

项与依托泊苷相关的文献（医药）

2106-07-05·Oncotarget

A comparison of R-EPOCH and R-CHOP as a first-line regimen inde novoDLBCL patients with high Ki-67 expression in a single institution

Article

作者: Wang, Yu ; Sun, Peng ; Bi, Xi-Wen ; Lin, Tong-Yu ; Liu, Pan-Pan ; Xia, Yi ; Jiang, Wen-Qi ; Huang, Jia-Jia ; Li, Zhi-Ming

Diffuse large B-cell lymphoma (DLBCL) patients with high Ki-67 expression receive limited benefits from R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) therapy. This study aims to compare the R-EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) and R-CHOP regimens as first-line therapy in DLBCL patients with high Ki-67 expression. Data from 44 untreated DLBCL patients with high Ki-67 expression receiving R-EPOCH therapy were matched with those from 132 untreated DLBCL patients with high Ki-67 expression receiving R-CHOP therapy based on the International Prognostic Index (IPI: age, Ann Arbor stage, performance status, LDH level, number of extranodal sites), gender, and Ki-67 expression. In the R-EPOCH group, 42/44 patients were eligible for response evaluation. A total of 35 patients (83.3%) achieved complete remission (CR); 6 patients (14.3%) achieved partial remission (PR); and one patient (2.4%) exhibited progressive disease (PD) after 2 cycles of therapy. Patients in the R-EPOCH group presented better survival outcomes than those in the R-CHOP group (3-year overall survival [OS]: 89.9% vs. 70.2%, p = 0.041; 3-year progression-free survival [PFS]: 86.6% vs. 59.7%, p = 0.024). The survival superiority of the R-EPOCH over the R-CHOP regimen persisted when considering only patients of low-to-intermediate IPI risk, but it was not observed in those of high IPI risk. Our data suggest that R-EPOCH could be superior to R-CHOP as a first-line regimen in DLBCL patients with high Ki-67 expression, especially in those of low-to-intermediate IPI risk.

2024-03-01·European Journal of Haematology

Identification of clinical factors impacting outcome in patients undergoing autologous hematopoietic cell transplantation after BEAM and TEAM conditioning

Article

作者: Wäsch, Ralph ; Finke, Jürgen ; Duque-Afonso, Jesús ; Gherman, Radu-Florian ; Engelhardt, Monika ; Duyster, Justus ; Strüßmann, Tim ; Bertz, Hartmut ; Marks, Reinhard ; Stolz, Daiana ; Ewald, Sophie ; Ihorst, Gabriele ; Zeiser, Robert

Abstract:

Organ dysfunction, including pulmonary function impairment, plays a key role in the choice of conditioning chemotherapy before autologous hematopoietic stem cell transplantation (auto‐HSCT). Replacement of BCNU/carmustine as part of BEAM (BCNU/carmustine, etoposide, cytarabine, and melphalan) conditioning protocol by thiotepa (TEAM) reduces pulmonary toxicity while maintaining efficacy. We retrospectively analyzed the association of clinical characteristics, comorbidities, and organ function with outcomes after conditioning with BEAM or TEAM. Three hundred ninety‐six patients undergoing auto‐HSCT (n = 333 with BEAM; n = 63 with TEAM) at our institution between 2008 and 2021 were included in this study. In the multivariate analysis, CO‐diffusion capacity corrected for hemoglobin (DLCOcSB) ≤ 60% of predicted, progressive disease (PD) before auto‐HSCT, Karnofsky performance score (KPS) ≤ 80%, HCT‐CI score ≥ 4, and cardiac disease before auto‐HSCT were associated with decreased overall survival (OS) in patients treated with BEAM. In contrast, only PD before auto‐HSCT was identified in patients treated with TEAM. Patients conditioned with BEAM and DLCOcSB ≤ 60% had higher non‐relapse mortality, including pulmonary cause of death. In summary, we have identified clinical and pulmonary risk factors associated with worse outcomes in patients conditioned with BEAM compared to TEAM. Our data suggest TEAM conditioning as a valid alternative for patients with comorbidities, including pulmonary dysfunction and/or poorer performance scores, before auto‐HSCT.

2024-02-16·Clinical Cancer Research

Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden

Article

作者: Losonczy, György ; Özgüroğlu, Mustafa ; Paz-Ares, Luis ; Xie, Mingchao ; Shrestha, Yashaswi ; Trukhin, Dmytro ; Jiang, Haiyi ; Chen, Yuanbin ; Ji, Jun Ho ; Mann, Helen ; Hotta, Katsuyuki ; Garassino, Marina Chiara ; Statsenko, Galina ; Reinmuth, Niels ; Godin-Heymann, Nadia ; Havel, Libor ; Poltoratskiy, Artem ; Bondarenko, Igor ; Goldman, Jonathan W ; Conev, Nikolay ; Lai, Zhongwu ; Hochmair, Maximilian J

Abstract:

Purpose::

In the CASPIAN trial, first-line durvalumab plus platinum-etoposide (EP) significantly improved overall survival (OS) versus EP alone in extensive-stage small cell lung cancer (ES-SCLC). We report exploratory analyses of CASPIAN outcomes by programmed cell death ligand-1 (PD-L1) expression and tissue tumor mutational burden (tTMB).

Experimental Design::

Patients were randomized (1:1:1) to durvalumab (1,500 mg) plus EP, durvalumab plus tremelimumab (75 mg) plus EP, or EP alone. Treatment effects in PD-L1 and tTMB subgroups were estimated using an unstratified Cox proportional hazards model.

Results::

The PD-L1 and tTMB biomarker-evaluable populations (BEP) comprised 54.4% (438/805) and 35.2% (283/805) of the intention-to-treat population, respectively. PD-L1 prevalence was low: 5.7%, 25.8%, and 28.3% had PD-L1 expression on ≥1% tumor cells (TC), ≥1% immune cells (IC), and ≥1% TCs or ICs, respectively. OS benefit with durvalumab plus EP versus EP was similar across PD-L1 subgroups, with HRs all falling within the 95% confidence interval (CI) for the PD-L1 BEP (0.47‒0.79). OS benefit with durvalumab plus tremelimumab plus EP versus EP was greater in PD-L1 ≥1% versus <1% subgroups, although CIs overlapped. There was no evidence of an interaction between tTMB and treatment effect on OS (durvalumab plus EP vs. EP, P = 0.916; durvalumab plus tremelimumab plus EP vs. EP, P = 0.672).

Conclusions::

OS benefit with first-line durvalumab plus EP in patients with ES-SCLC was observed regardless of PD-L1 or tTMB status. PD-L1 expression may prove to be a useful biomarker for combined treatment with PD-(L)1 and CTLA-4 inhibition, although this requires confirmation with an independent dataset.See related commentary by Rolfo and Russo, p. 652

406

项与依托泊苷相关的新闻（医药）

2024-04-25

·GlobeNewswire-Health Care

Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene

Apollomics’ partner in China, Avistone, received approval from National Medical Products Administration of China to expand the use of vebreltinib to the treatment of gliomas with PTPRZ1-MET fusion gene Approval based on results from a randomized Phase 2/3 trial FOSTER CITY, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that its partner in China, Avistone Biotechnology Co. Ltd. (Avistone), received approval from the National Medical Products Administration (NMPA) of China for vebreltinib (APL-101) for the treatment of adult patients with isocitrate dehydrogenase (IDH) mutant astrocytoma (WHO Grade 4) or glioblastoma with a history of low-grade disease who have the PTPRZ1-MET fusion (ZM fusion) gene and have failed previous treatments. This supplemental New Drug Application (sNDA) approval makes vebreltinib the world’s first c-Met inhibitor approved for treatment of Central Nervous System (CNS) tumor with c-Met alteration, and follows the NMPA’s November 2023 approval of vebreltinib for the treatment of patients with Met Exon 14 skipping non-small cell lung cancer (NSCLC). "The NMPA’s approval of vebreltinib in gliomas is an important, first-in-class approval as it demonstrates vebreltinib’s CNS penetration ability and c-Met inhibitory activity in the tumors there," said Guo-Liang Yu, Ph.D., Chairman and Chief Executive Officer of Apollomics. "Our collaboration with Avistone, which includes data-sharing, and our ongoing global SPARTA trial with vebreltinib underscores our commitment and the potential to develop vebreltinib for treating patients with solid tumors with c-Met alterations globally, outside of China.” Gliomas are difficult-to-treat primary malignant intracranial tumors accounting for about 46% of all intracranial tumors. Surgery, radiation treatment, and chemotherapy are current standard treatment strategies for gliomas with poor prognoses. The overall survival (OS) rate for malignant glioma patients is less than 10% after five years. Prior studies in Chinese patients have found that about 12% of gliomas have MET fusion, among which the representative type ZM fusion occurs in about 14% of glioblastomas with a history of lower-grade disease, often co-occurring with Met Exon 14 skipping mutations, and is associated with a poorer prognosis. The proportion of this glioblastoma genotype in the U.S. and EU is less known. Vebreltinib, Apollomics’ most advanced product candidate in the U.S., is a potent, small molecule, orally bioavailable and highly selective c-Met inhibitor that works by inhibiting the aberrant activation of the HGF/c-Met axis, a key pathway involved in tumor growth, proliferation, and the development of resistance to certain targeted therapies. The approval of vebreltinib for the ZM fusion-positive glioma indication in China is based on the positive results of Avistone’s FUGEN study (NCT06105619), a randomized, two-arm, multicenter Phase 2/3 clinical study that was conducted in China. This 84-patient study compared the efficacy and safety of vebreltinib with the dose-dense regimen of temozolomide or the combination of etoposide and cisplatin, with OS as the primary endpoint. The median OS for the vebreltinib monotherapy regimen was 6.31 months, compared to 3.38 months for the control group, reducing the risk of death by 48% and significantly improving the survival of patients with recurrent relapsing ZM fusion glioma, with an acceptable safety profile. In the ongoing global SPARTA study being conducted by Apollomics that includes U.S. and European patients, similar to the vebreltinib treated patients in the FUGEN study in China, a median survival of 6.5 months has been observed to date in the 25 patients with recurrent relapsing CNS tumors with c-Met alterations treated with vebreltinib. Eight of these 25 patients with recurrent relapsing glioma had centrally confirmed ZM fusion glioma, where the median OS was also 6.5 months. These preliminary data support cross-region similarity of patient response to treatment with vebreltinib. Under the partnership agreement, Avistone holds the exclusive rights to vebreltinib in China, Hong Kong and Macau, while Apollomics retains the exclusive rights in the rest of the world, including the U.S, and the partners have access to each other’s data. This collaboration enables both companies to leverage their strengths and maximize the benefit of vebreltinib worldwide. About SPARTA Apollomics is conducting a multi-cohort Phase 2 study of vebreltinib, SPARTA, at over 90 centers in 12 countries investigating the efficacy and safety of vebreltinib in Met Exon 14 skipping NSCLC. Cohorts A-1 is recruiting in first line Met Exon 14 skipping NSCLC subjects and Cohort A-2 is recruiting in pretreated (> 2L) Met Exon 14 skipping NSCLC subjects. In addition, Cohort C includes histology agnostic c-Met amplified cancers (excluding primary CNS tumors) and Cohort C-1 includes NSCLC harboring c-Met amplification and wild-type epidermal growth factor receptor (EGFR). About Apollomics Inc. Apollomics Inc. is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. Apollomics currently has a pipeline of nine drug candidates across multiple programs, six of which are currently in the clinical stage of development. Apollomics’ lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia. For more information, please visit www.apollomicsinc.com. Cautionary Statement Regarding Forward-Looking Statements This press release includes statements that constitute “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements, other than statements of present or historical fact included in this press release, regarding clinical trials and results, as well as the Company’s strategy, business plans and objectives of management are forward-looking statements. In addition, Apollomics cautions you that the forward-looking statements contained in this press release are subject to unknown risks, uncertainties and other factors, including: (i) Apollomics’ ability to raise additional capital to meet its operating cash requirements and expectations regarding incurring net losses and net operating cash outflows; (ii) the ability of Apollomics to maintain the listing of its Class A ordinary shares on Nasdaq (iii) Apollomics’ ability to achieve successful clinical results; (iv) Apollomics’ ability to commercialize its product candidates; (v) Apollomics’ ability to develop and maintain effective internal controls over financial reporting; (vi) the impact of any current or new government regulations in the United States and China affecting Apollomics’ operations; (vii) Apollomics’ ability to obtain licensing of third-party intellectual property rights for future discovery and development of Apollomics’ oncology projects; (viii) the failure to protect Apollomics’ intellectual property; (v) breaches in data security; and other risks included in the Annual Report on Form 20-F filed with the SEC and other SEC filings that are available publicly on the SEC’s website at www.sec.gov. Apollomics undertakes no obligation to update publicly any of these forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable laws. CONTACTSInvestor RelationsPeter VozzoICR WestwickePeter.Vozzo@westwicke.com+1-443-213-0505 Media RelationsSean LeousICR WestwickeSean.Leous@westwicke.com+1-646-866-4012

上市批准临床2期临床结果放射疗法

2024-04-25

·BiG生物创新社

ASCO 2024丨这些中国临床专家，将分享最新重磅研究

2024年美国临床肿瘤学会(ASCO)年会将于5月31日到6月4日在芝加哥举办，是世界上规模最大、学术水平最高、最具权威性的临床肿瘤学会议，会议汇集了全球肿瘤学医生和专业人士、患者倡导者、工业界代表和主要媒体，共同探讨当前国际最前沿的研究发现和临床试验成果。ASCO成立于1964年,是世界上最大、最具影响力的肿瘤专业学术组织,致力于癌症的预防、治疗及改善对患者的护理。ASCO在全球150多个国家和地区拥有超过45,000名成员。4月24日晚，ASCO官网公布了本次大会的研究标题，几十余名中国专家将在世界舞台上展示其研究成果，报告涵盖了多个瘤种的最新治疗策略和技术，展示了中国在全球癌症研究中的重要地位和贡献。世易编辑团队精心整理了中国专家们的研究报告，供您参考。全体大会报告Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable stage (stg) III epidermal growth factor receptor-mutated (EGFRm) NSCLC: Primary results of the phase 3 LAURA study. Abstract: LBA4 · Suresh S. Ramalingam教授，美国埃默里大学Winship癌症研究所· 陆舜教授，上海交通大学附属胸科医院口头报告Lung Cancer—Non-Small Cell MetastaticSacituzumab tirumotecan (SKB264/MK-2870) in combination with KL-A167 (anti-PD-L1) as first-line treatment for patients with advanced NSCLC from the phase II OptiTROP-Lung01 study. Abstract: 8502 · 方文峰教授，中山大学肿瘤防治中心 Ivonescimab combined with chemotherapy in patients with EGFR-mutant non-squamous non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor treatment (HARMONi-A): A randomized, double-blind, multi-center, phase 3 trial. Abstract: 8508 · 张力教授，中山大学肿瘤防治中心 Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers Adjuvant icotinib of 12 months or 6 months versus observation following adjuvant chemotherapy for resected EGFR-mutated stage II–IIIA non-small-cell lung cancer (ICTAN, GASTO1002): A randomized phase 3 trial. Abstract: 8004 ·王思愚教授，中山大学肿瘤防治中心 A phase II randomized trial evaluating consolidative nivolumab in locally advanced non-small cell lung cancer post neoadjuvant chemotherapy plus nivolumab and concurrent chemoradiotherapy (GASTO-1091). Abstract: 8008 · 刘慧教授，中山大学肿瘤防治中心 Taiwan national lung cancer early detection program for heavy smokers and non-smokers with family history of lung cancer. Abstract: 8009 · Pan-Chyr Yang, MD, PhD，台湾大学医学院 Gastrointestinal Cancer—Colorectal and Anal Neoadjuvant treatment of IBI310 (anti-CTLA-4 antibody) plus sintilimab (anti-PD-1 antibody) in patients with microsatellite instability-high/mismatch repair-deficient colorectal cancer: Results from a randomized, open-labeled, phase Ib study. Abstract: 3505 · 徐瑞华教授，中山大学肿瘤防治中心 Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant Phase I study of CN201, a novel CD3xCD19 IgG4 bispecific antibody, in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia. Abstract: 6505 · 王迎教授，中国医学科学院血液病医院 Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia CLAMP: A phase II prospective study of camrelizumab combined with pegaspargase, etoposide, and high-dose methotrexate in patients with natural killer (NK)/T-cell lymphoma. Abstract: 7002 · 刘涛教授，华中科技大学同济医学院附属协和医院 Tucidinostat plus R-CHOP in previously untreated diffuse large B-cell lymphoma with double expression of MYC and BCL2: An interim analysis from the phase III DEB study. Abstract: LBA7003 · 赵维莅教授，上海交通大学医学院附属瑞金医院 Hematologic Malignancies—Plasma Cell DyscrasiaPhase 3 study results of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) versus VRd for transplant-ineligible patients with newly diagnosed multiple myeloma (IMROZ). Abstract: 7500 ·Thierry Facon, MD，University of Lille, CHU Lille·刘卓刚教授，中国医科大学附属盛京医院Central Nervous System Tumors Efficacy and safety of the vebreltinib in patients with previously treated, secondary glioblastoma/IDH mutant glioblastoma with PTPRZ1-METFUsion GENe (FUGEN): A randomised, multicentre, open-label, phase II/III trial. Abstract: 2003 · Zhaoshi Bao, MD, PhD，首都医科大学附属北京天坛医院 High-dose almonertinib in treatment-naïve EGFR-mutated NSCLC with CNS metastases: Efficacy and biomarker analysis. Abstract: 2007 · 范云教授，浙江省肿瘤医院 SarcomaUpdated efficacy results of olverembatinib (HQP1351) in patients with tyrosine kinase inhibitor (TKI)-resistant succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GIST) and paraganglioma. Abstract: 11502 · 邱海波教授，中山大学肿瘤防治中心 Sintilimab, doxorubicin and ifosfamide (AI) as first-line treatment in patients with advanced undifferentiated pleomorphic sarcoma (UPS), synovial sarcoma (SS), myxoid liposarcoma (MLPS) and de-differentiated liposarcoma (DDLPS): A single-arm phase 2 trial. Abstract: 11505 · 罗志国教授，复旦大学附属肿瘤医院 ARTEMIS-002: Phase 2 study of HS-20093 in patients with relapsed or refractory osteosarcoma. Abstract: 11507 · 谢璐教授，北京大学人民医院 Head and Neck Cancer Adjuvant PD-1 blockade with camrelizumab in high-risk locoregionally advanced nasopharyngeal carcinoma (DIPPER): A multicenter, open-label, phase 3, randomized controlled trial. Abstract: LBA6000 · 刘需教授，中山大学肿瘤防治中心 Tislelizumab versus placebo combined with induction chemotherapy followed by concurrent chemoradiotherapy and adjuvant tislelizumab or placebo for locoregionally advanced nasopharyngeal carcinoma: Interim analysis of a multicenter, randomized, placebo-controlled, double-blind, phase 3 trial. Abstract: 6001 · 陈秋燕教授，中山大学肿瘤防治中心 Endostar combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone for locoregionally advanced nasopharyngeal carcinoma (LA-NPC): A phase III, prospective, randomised-controlled, multicenter clinical trial. Abstract: 6002 · 康敏教授，广西医科大学第一附属医院 Developmental Therapeutics—ImmunotherapyClaudin18.2-targeted chimeric antigen receptor T cell-therapy for patients with gastrointestinal cancers: Final results of CT041-CG4006 phase 1 trial. Abstract: 2501 · 齐长松教授，北京大学肿瘤医院 A potential best-in-class BCMA-CD19 bispecific CART with advanced safety by self-inhibiting IFNG signaling during CRS. Abstract: 2502 · Lei Xue Efficacy and safety of LM-108, an anti-CCR8 monoclonal antibody, in combination with an anti-PD-1 antibody in patients with gastric cancer: Results from phase 1/2 studies. Abstract: 2504 · Chang Liu, MD，北京大学肿瘤医院Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology Phase I/II first-in-human study to evaluate the safety and efficacy of tissue factor-ADC MRG004A in patients with solid tumors.Abstract: 3002· Wungki Park, MD, MS，美国纪念斯隆凯瑟琳癌症中心· 张剑教授，复旦大学附属肿瘤医院Updated safety and efficacy data of combined KRAS G12C inhibitor (glecirasib, JAB-21822) and SHP2 inhibitor (JAB-3312) in patients with KRAS p.G12C mutated solid tumors. Abstract: 3008 · 赵军教授，北京大学肿瘤医院快速口头摘要报告 Lung Cancer—Non-Small Cell Metastatic A multinational pivotal study of sunvozertinib in platinum pretreated non-small cell lung cancer with EGFR exon 20 insertion mutations: Primary analysis of WU-KONG1 study. Abstract: 8513 · James Chih-Hsin Yang 教授，台大肿瘤中心 Efficacy and safety of taletrectinib in patients with advanced or metastatic ROS1+ non–small cell lung cancer: The phase 2 TRUST-I study. Abstract: 8520 · 李玮教授，同济大学附属上海市肺科医院 Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers Overall survival of adebrelimab plus chemotherapy and sequential thoracic radiotherapy as first-line treatment for extensive-stage small cell lung cancer. Abstract: 8014 · 陈大卫教授，山东省肿瘤医院 Breast Cancer—Metastatic ACE-Breast-02: A pivotal phase II/III trial of ARX788, a novel anti-HER2 antibody-drug conjugate (ADC), versus lapatinib plus capecitabine for HER2+ advanced breast cancer (ABC). Abstract: 1020 · 胡夕春教授，复旦大学附属肿瘤医院 Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary Efficacy and safety of cadonilimab in combination with pulocimab and paclitaxel as second-line therapy in patients with advanced gastric or gastroesophageal junction (G/GEJ) cancer who failed immunochemotherapy: A multicenter, double-blind, randomized trial. Abstract: 4012 · 张小田教授，北京大学肿瘤医院 Phase I study of C-CAR031, a GPC3-specific TGFβRIIDN armored autologous CAR-T, in patients with advanced hepatocellular carcinoma (HCC). Abstract: 4019 · 章琦教授，浙江大学医学院附属第一医院肝胆胰外科 Gastrointestinal Cancer—Colorectal and Anal Total neoadjuvant treatment with long-course radiotherapy versus concurrent chemoradiotherapy in local advanced rectal cancer with high risk factors (TNTCRT): A multicenter, randomized, open-label, phase 3 trial. Abstract: LBA3511 · Xin Wang, MD，四川大学华西医院 Phase I trial of hypoxia-responsive CEA CAR-T cell therapy in patients with heavily pretreated solid tumor via intraperitoneal or intravenous transfusion. Abstract: 3514 · Hangyu Zhang，浙江大学医学院第一附属医院 Three-year disease-free survival after transanal vs. laparoscopic total mesorectal excision for rectal cancer (TaLaR): A randomized clinical trial. Abstract: 3516 · 康亮教授，中山大学附属第六医院 Genitourinary Cancer—Kidney and Bladder Camrelizumab plus apatinib for previously treated advanced adrenocortical carcinoma: A single-arm, open-label, phase 2 trial. Abstract: 4511 · Zhigong Wei，四川大学华西医院 Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant Latest results of a phase 2 study of IMM01 combined with azacitidine (AZA) as the first-line treatment in adults with higher risk myelodysplastic syndromes (MDS). Abstract: 6510 · Wei Yang，中国医科大学附属盛京医院 Safety and efficacy of CD7-CAR-T cell in patients with relapsed/refractory T-lymphoblastic leukemia/lymphoma: Phase I dose-escalation/dose-expansion study. Abstract: 6515 · Lijuan Hu, MD, 北京大学人民医院 Hematologic Malignancies—Plasma Cell Dyscrasia OriCAR-017, a novel GPRC5D-targeting CAR-T, in patients with relapsed/refractory multiple myeloma: Long term follow-up results of phase 1 study (POLARIS). Abstract: 7511 · Shan Fu，浙江大学医学院附属第一医院 Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia Timdarpacept (IMM01) in combination with tislelizumab in prior anti-PD-1 failed classical Hodgkin lymphoma: An open label, multicenter, phase II study (IMM01-04) evaluating safety as well as preliminary anti-tumor activity. Abstract: 7017 · Zhenjiu Wang, MD Gynecologic Cancer Efficacy and safety of sintilimab plus paclitaxel and cisplatin as neoadjuvant therapy for locally advanced cervical cancer: A phase II trial. Abstract: 5512 ·刘继红教授，中山大学肿瘤防治中心 Nimotuzumab plus concurrent chemoradiotherapy for locally advanced cervical squamous cell carcinoma: The randomized, phase 3 CC3 study. Abstract: 5514 ·王俊杰教授，北京大学第三人民医院 A phase III randomized, double-blinded, placebo-controlled study of suvemcitug combined with chemotherapy for platinum-resistant ovarian cancer (SCORES). Abstract: LBA5516 · 袁光文教授，中国医学科学院肿瘤医院 Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): A final overall survival analysis of a multicenter, open-label, randomized, phase 3 trial. Abstract: 5520 · 臧荣余教授，复旦大学附属中山医院 Head and Neck Cancer Preliminary results of phase I/II study to evaluate safety and efficacy of combination pucotenlimab with epidermal growth factor receptor-ADC (EGFR-ADC) MRG003 in patients with EGFR positive solid tumors. Abstract: 6013 · 阮丹云教授，中山大学肿瘤防治中心 Covalent FAPI PET enables accurate management of medullary thyroid carcinoma: a prospective single-arm comparative clinical trial. Abstract: LBA6018 · Ziren Kong, MD, 中国医学科学院北京协和医学院 Sarcoma A phase II study of anlotinib and an anti-PDL1 antibody in patients with alveolar soft part sarcoma: Results of expansion cohorts. Abstract: 11515 · 刘佳勇教授，北京大学肿瘤医院 Phase 1 study of NB003, a broad-spectrum KIT/PDGFRα inhibitor, in patients with advanced gastrointestinal stromal tumors (GIST). Abstract: 11518 · 李健教授，北京大学肿瘤医院 Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology Results of a phase 1/2 study of MHB088C: A novel B7H3 antibody-drug conjugate (ADC) incorporating a potent DNA topoisomerase I inhibitor in recurrent or metastatic solid tumors. Abstract: 3012 · 沈琳教授，北京大学肿瘤医院 9MW2821, a nectin-4 antibody-drug conjugate (ADC), in patients with advanced solid tumor: Results from a phase 1/2a study. Abstract: 3013 · 张剑教授，复旦大学附属肿瘤医院 Developmental Therapeutics—Immunotherapy Phase I study of GUCY2C CAR-T therapy IM96 in patients with metastatic colorectal cancer. Abstract: 2518 · 齐长松教授，北京大学肿瘤医院 Safety and preliminary efficacy results of IBI389, an anti-CLDN18.2/CD3 bispecific antibody, in patients with solid tumors and gastric or gastro-esophageal tumors: A phase 1 dose escalation and expansion study. Abstract: 2519 · 郑莉教授，四川大学华西医院 Symptom Science and Palliative Care Effect of nurse-led multi-disciplinary treatment on patients with head and neck tumors: A randomized controlled trial. Abstract: 12013 · Jingjing Wang, MD，四川大学华西医院肿瘤中心临床科学研讨会A phase 1/2 study of the TORC1/2 inhibitor onatasertib combined with toripalimab in patients with advanced solid tumors: Cervical cancer cohort. Abstract: 5509 · Hui Xie，德琪医药有限公司临床研发部 KRYSTAL-12: Phase 3 study of adagrasib versus docetaxel in patients with previously treated advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation. Abstract: LBA8509 · Tony S. K. Mok 教授，香港大学 Sacituzumab tirumotecan (SKB264/MK-2870) in patients (pts) with previously treated locally recurrent or metastatic triple-negative breast cancer (TNBC): Results from the phase III OptiTROP-Breast01 study. Abstract: 104 · 樊英教授，中国医学科学院肿瘤医院 Efficacy of disitamab vedotin (RC48) plus tislelizumab and S-1 as first-line therapy for HER2-overexpressing advanced stomach or gastroesophageal junction adenocarcinoma: A multicenter, single-arm, phase II trial (RCTS). Abstract: 4009 · 刘联教授，山东大学齐鲁医院 A novel and uniquely designed bispecific antibody (LBL-024) against PD-L1 and 4-1BB in patients with advanced malignant tumors and neuroendocrine carcinoma: A report of safety and robust efficacy of LBL-024 monotherapy in phase I/II, first-in-human, open-label, multicenter, dose escalation/expansion study. Abstract: 4010 · 张盼盼医生，北京大学肿瘤医院 Safety and efficacy of IBI389, an anti-CLDN18.2/CD3 bispecific antibody, in patients with advanced pancreatic ductal adenocarcinoma: Preliminary results from a phase 1 study. Abstract: 4011 · 郝继辉教授，天津医科大学肿瘤医院 Neoadjuvant sintilimab and platinum-doublet chemotherapy followed by transoral robotic surgery for HPV-associated resectable oropharyngeal cancer: Single-arm, phase II trial. Abstract: 6011 · 宋明教授，中山大学肿瘤防治中心 BiG 十周年预告本次BiG十周年庆典，将首次分为国内和国际篇章，以原创科学和临床需求为出发点，讨论创新技术平台和创新疗法（PROTACT/分子胶、双抗/ADC、siRNA/ASO、CGT、AI制药）的重大进展和发展前景，十年一药曙光现，大浪淘沙始见金！▼报名参会会议门票：审核制(免费)；含主论坛+分论坛，不含餐；优先biotech/Pharma、临床、院校科学家共建Biomedical创新生态圈！如何加入BiG会员？

ASCO会议临床结果

2024-04-23

·E药经理人

一场转化医学的胜利！伯瑞替尼开启脑胶质瘤治疗精准靶向时代！

仅仅5个月！北京鞍石生物科技股份有限公司（鞍石生物）的MET抑制剂再下一城！2024年4月23日，中国国家药品监督管理局（NMPA）公布正式批准北京鞍石生物科技股份有限公司（鞍石生物科技）全资子公司北京浦润奥生物科技有限责任公司自主研发的1类创新药伯瑞替尼肠溶胶囊（商品名：万比锐®，以下简称为伯瑞替尼）用于既往治疗失败的具有PTPRZ1-MET融合基因的IDH突变型星形细胞瘤（WHO 4级）或有低级别病史的胶质母细胞瘤成人患者。这是继非小细胞肺癌适应症后，伯瑞替尼在中国获批的第二项适应症，也是我国在脑胶质瘤MET靶向治疗领域首个完全获批的小分子靶向药物。作为一款高选择性小分子MET激酶抑制剂，伯瑞替尼凭借卓越的疗效和安全性，其肺癌与脑胶质瘤适应症分别于2021年2月和2022年9月先后被NMPA药品审评中心（CDE）纳入突破性治疗品种、优先审评，并在2023年11月获批首个适应症，用于治疗MET 14外显子跳变的局部晚期或转移性非小细胞肺癌（NSCLC）成人患者。仅仅不到半年时间，新适应症的获批，不仅为伯瑞替尼开拓了更广阔的市场空间，同时，作为目前国内首个治疗脑胶质瘤的MET抑制剂，也将此前以手术为主的脑胶质瘤治疗领域带入了精准靶向时代。一马当先，啃下“硬骨头”很长一段时间，脑胶质瘤都被看作肿瘤治疗领域一块难啃的“硬骨头”。胶质瘤是起源于神经胶质细胞的肿瘤，恶性胶质瘤5年总生存率（OS）不足10%，5年病死率在全身肿瘤中仅次于胰腺癌[1]；胶质母细胞瘤则是其中最常见和最致命的一种类型，不仅恶性程度高，生存预后也更差，基本治疗方案原则上以手术为主，辅以放疗、化疗等，但临床效果往往不尽如人意。直到近年来，随着基因检测技术的不断发展、完善和应用，脑胶质瘤起源和恶性进展过程中的关键驱动性基因突变逐渐被揭示，靶向治疗被认为是未来脑胶质瘤治疗的新希望。2021年，《WHO中枢神经系统肿瘤分类标准（第五版）》更新，强调基于组织病理学和分子病理学的整合诊断，该分类标准纳入了新的分子标志物，并鼓励将更多分子诊断新技术、新方法用于临床[2]。其中也提出MET异常与脑胶质瘤的发生发展密切相关，这一发现在临床诊治上意义重大，而鞍石生物比绝大多数同行更早地发现了这一点。早在2014年，鞍石生物便携手首都医科大学附属北京天坛医院、北京市神经外科研究所江涛教授团队发现PTPRZ1-MET融合基因（简称“ZM融合基因”）主要存在于既往有低级别病史的胶质母细胞瘤患者中，且是胶质母细胞瘤恶性进展的关键驱动因子，为药物靶向治疗提供了理论依据。基于此，鞍石生物迅速开展了伯瑞替尼应用于脑胶质瘤适应症的研发工作。2018年，伯瑞替尼治疗脑胶质瘤的Ⅰ期临床研究结果便已发表在国际顶级期刊CELL杂志，ZM融合基因阳性（部分伴METex14跳突）的复发高级别脑胶质瘤患者的疾病控制率DCR 达到66.7%[3]。该项研究数据备受关注，为脑胶质瘤的精准诊疗打开了更多思路。此后“相信成为确信”。鞍石生物继续加码其在脑胶质瘤研究领域上的投入。伯瑞替尼在治疗ZM融合基因阳性IDH突变的WHO 4级星型细胞瘤或有低级别病史的胶质母细胞瘤患者的Ⅱ/Ⅲ期关键注册临床研究（FUGEN研究）结果显示：相较于替莫唑胺剂量密度方案或顺铂联合依托泊苷方案，伯瑞替尼单药方案mOS为 6.31个月，对照组为3.38个月，降低了48%的死亡风险，可显著改善患者生存[4]。“我们要打造的是脑胶质瘤的First-in-class产品。”2024年，这一目标随着伯瑞替尼新适应症的获批得以实现。虽然MET已成为当下癌症领域的热门研究靶点之一，目前在全球范围内共五款MET抑制剂获批，但除伯瑞替尼外均只针对NSCLC患者。一场既稳又专的胜利不论临床专家还是业界投资人，讨论到伯瑞替尼几乎离不开的一个词便是“转化医学”。鞍石生物创始人、董事长兼CEO石和鹏博士认为：“这是一款由中国临床专家发现致病基因，并由中国创新药企业负责转化的典型基础科研转化案例。”虽然近年来中国创新药已经进入新阶段，取得的成绩也有目共睹，但科研转化仍是创新的薄弱环节。鞍石生物为什么能够获得“胜利”？首先，得益于鞍石生物始终坚持“解决真正的临床需求”为理念。2012年，鞍石生物开始创业，当时正是中国创新药研发的萌芽时期。后来，国内很多Biotech经历了从“讲故事”获得大额融资的高光时刻，到同质化研发泛滥的漫漫寒冬。这一过程中，鞍石生物始终坚定着三点：一是能否真正解决临床需求，二是靶点是否得到充分验证，三是小分子的成药性，“比起讲故事，我们更看重帮助患者。”因此，鞍石生物坚定地选择了一条难而正确的路，将伯瑞替尼的临床转化成果聚焦于脑胶质瘤这一全球最难治且只有较少研发者参与的适应症上，最终由国内基础科研成功转化为脑胶质瘤First-in-class药物。伯瑞替尼的“胜利”也充分证明了，临床医生携手创新药企推进转化医学的模式在中国是完全走得通的。其次，除了坚定的信念和初衷，鞍石生物在公司战略定位和战略布局上同样下足了功夫。从成立伊始，鞍石生物便看准脑科学研究的突破，“未来潜力是巨大的。”据世界卫生组织的统计，脑相关疾病是所有疾病里社会负担最大的，占28%，超过了心血管疾病和癌症[5]。从顶层设计方面，我国不断加大对脑部疾病研究的投入。2021年，国家科技部网站正式发布科技创新2030“脑科学与类脑研究”重大项目，国家拨款经费预计超过31.48亿元[6]。这也标志着酝酿6年多的“中国脑计划项目”正式启动。因此，脑疾病药物这一隐秘的领域也迅速成为“兵家必争之地”，定位准、站位高的鞍石生物，依托既稳又专的战略布局，不仅站在了行业前列，也收获了一众投资机构的青睐。2023年12月28日，鞍石生物完成了B轮10亿元人民币融资。本轮融资由国投招商和IDG资本联合领投，燕创集团、凯辉基金跟投，现有股东贝恩资本继续追加投资。鞍石生物“逆势而上”的融资，足以证明其基于科学创新的核心竞争力和战略布局能力。有了穿越寒冬的资本，鞍石生物才能继续加固自身的“护城河”。鞍石生物在开拓伯瑞替尼和安达替尼两款药物双靶联合的广泛场景的同时，积极推进在研管线的临床试验，加快潜在化合物的筛选，增加“研发体系厚度”。同时，鞍石生物也从未放弃打造自己的商业化造血能力。在团队成立伊始，石和鹏博士便用当企业家而不是科学家的创业思维来要求自己，“创新药企发展的每一个环节都不能躲避。”鞍石生物瞄准了自建商业化队伍的目标。随着2023年11月伯瑞替尼NSCLC适应症上市获批，鞍石生物已经建立了一支由来自国内外优秀制药企业的业务精英组成的商业化团队，覆盖全国25个省份、近千家医院，以及数百家商业公司和零售终端。除国内的商业化活动外，鞍石生物同时在紧锣密鼓地布局“出海”。2022年8月，伯瑞替尼已被美国食品药品监督管理局（FDA）授予孤儿药资格（Orphan Drug Designation, ODD）。目前，鞍石生物正在大力推动中美双申报的进程。“商业化是创新药企发展过程中必须跨过的鸿沟，跨过去就一定能成为我们的核心竞争力。”凭借优秀的创新研发实力、高效的执行效率和深远的管线布局战略，鞍石生物有信心筑牢自身的“护城河”，持续推出更多具有临床先进性的创新产品，并将在商业化阶段获得更大的成功。声明：以上信息皆来源于公开信息，不作为推荐、投资使用。参考文献：[1] 国家卫生健康委员会医政医管局, 等. 中华神经外科杂志,2022,38(8):757-777.[2] Louis DN, et al. Neuro Oncol. 2021 Aug 2;23(8):1231-1251.[3] Hu H, et al. Cell. 2018 Nov 29;175(6):1665-1678.e18.[4] 伯瑞替尼FUGEN研究（NCT06105619）.[5] WHO 2021年统计www.who.int/zh/news .[6] www.yicai.com/news/101177358.html .NMPA截图来源：https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20240423143915191.html

优先审批突破性疗法

100 项与依托泊苷相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00125	依托泊苷	L01CB01	DB00773

研发状态

适应症	最高研发状态	国家/地区	公司
小细胞肺癌	批准上市	日本更多	Clinigen Ltd. 更多
广泛期小细胞肺癌	临床3期	西班牙更多	AstraZeneca PLC 更多
小儿眼内视网膜母细胞瘤	临床2期	新加坡更多	The Hospital for Sick Children 更多
横纹肌肉瘤	无进展	澳大利亚更多	National Cancer Institute 更多
复发性外阴间充质瘤	无进展	澳大利亚更多	National Cancer Institute 更多

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02481310 (DACIPHOR, Pubmed)	临床1/2期	维持 MYC expression	-	DA-EPOCH-R plus ixazomib	顧選鏇積鹽觸壓餘淵蓋(衊襯鏇窪構鬱齋壓遞壓) = 襯遞鹽衊願壓遞壓築鏇繭鬱鏇糧膚積獵願積鑰 (醖網憲廠願網窪糧艱餘 ) 更多	积极	2024-04-09
NCT00630565 (CTgov)	临床2/3期	急性髓性白血病	12	total-body irradiation+etoposide+cyclophosphamide+sargramostim+dexamethasone	廠繭蓋網淵廠淵製積膚(襯憲廠簾鹹範淵齋廠鬱) = 鏇鑰淵鏇糧構淵範築觸壓願襯獵淵願製鹽齋製 (襯艱獵製膚餘選憲繭觸, 襯蓋鹽齋觸鹹築襯廠襯 ~ 膚糧鬱鏇簾選鏇餘糧醖) 更多	-	2024-01-29
NCT02763579 (IMpower133, Pubmed)	临床3期	广泛期小细胞肺癌维持	403	Carboplatin, Etoposide and Atezolizumab	淵衊壓顧鬱鹹蓋積鑰鹽(夢衊憲襯艱鑰蓋蓋網顧) = 廠糧鬱鹽醖淵鑰廠壓蓋範鏇選選製遞蓋夢製鑰 (廠製製醖選夢糧餘糧顧 )	积极	2024-01-27
ASCO_GI2024	N/A	胰岛细胞癌二线 POLE P286R mutation \| BRAF V600E mutation	20	Platinum combination chemotherapy	願廠簾艱蓋糧範積夢膚(製簾餘願膚繭夢遞鑰餘) = Grade 3 or higher toxicity was observed in 13 patients 廠醖壓壓構襯蓋糧獵糧 (淵壓遞觸鬱艱範觸遞艱 )	-	2024-01-18
ASCO_GI2024	N/A	胰岛细胞癌二线 POLE P286R mutation \| BRAF V600E mutation	20	Regimen containing irinotecan, 5-FU, paclitaxel, ramucirumab, and nivolumab		-	2024-01-18
NCT02385110 (CTgov)	临床2期	噬血细胞性淋巴组织细胞增多症 \| 白血病	18	Phone Call+Etoposide+Dexamethasone+Methotrexate+Alemtuzumab (Group 1: Alemtuzumab + Etoposide + Dexamethasone)	襯製衊糧繭網糧鹽鑰鬱(製範鹽壓夢餘餘蓋積糧) = 鏇積衊鑰獵鹽鹹齋顧觸網製艱蓋積築鑰餘鬱鏇 (艱鑰製獵襯繭膚壓選獵, 廠鏇壓廠膚蓋構網夢憲 ~ 構鑰願鬱壓鑰壓餘夢鏇) 更多	-	2024-01-17
NCT02385110 (CTgov)	临床2期	噬血细胞性淋巴组织细胞增多症 \| 白血病	18	Phone Call+Etoposide+Tocilizumab+Dexamethasone+Methotrexate+Alemtuzumab (Group 2: Etoposide + Dexamethasone + Tocilizumab)	襯製衊糧繭網糧鹽鑰鬱(製範鹽壓夢餘餘蓋積糧) = 淵襯醖鑰網糧願網壓願網製艱蓋積築鑰餘鬱鏇 (艱鑰製獵襯繭膚壓選獵, 襯範繭繭鏇衊觸顧鑰獵 ~ 鏇鑰憲齋獵簾夢膚鏇鏇) 更多	-	2024-01-17
ASH2023	N/A	急性早幼粒细胞白血病	60	Oral VP16 + ATRA + RIF	襯範膚淵膚繭繭餘艱壓(餘獵範構願蓋鑰積壓獵) = 壓窪簾積憲繭網餘艱獵廠壓鹽淵範夢壓糧廠餘 (餘網廠廠蓋積窪夢範醖 ) 更多	-	2023-12-11
ASH2023	N/A	急性早幼粒细胞白血病	60	Intravenous cytoreductive chemotherapy + ATRA + RIF	襯範膚淵膚繭繭餘艱壓(餘獵範構願蓋鑰積壓獵) = 觸製願觸齋繭鹽鹽蓋夢廠壓鹽淵範夢壓糧廠餘 (餘網廠廠蓋積窪夢範醖 ) 更多	-	2023-12-11
ASH2023	N/A	原发性中枢神经系统淋巴瘤巩固	72	Methotrexate-Temozolomide-Rituximab Induction	鑰膚觸齋鹽鏇衊艱壓鏇(蓋簾壓壓壓鏇餘遞選蓋) = 積壓廠衊鹹簾觸鑰觸廠選餘積製艱獵襯範鑰窪 (鬱選醖鑰齋積願淵膚鹽 ) 更多	-	2023-12-11
NCT03118466 (ASH2023)	临床2期	复发性急性髓细胞白血病	40	Lenalidomide	獵簾鏇繭遞構鑰鏇選艱(製願築蓋淵醖觸廠築範) = 餘網鏇膚積願襯範鏇餘願餘糧齋襯餘網襯製膚 (窪構繭範淵夢製築鑰簾 ) 更多	-	2023-12-10
ASH2023	N/A	成人T细胞白血病/淋巴瘤巩固 \| 维持	16	Brentuximab Vedotin with Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (BV-CHEP)	觸醖夢廠製醖憲餘繭構(餘艱積齋顧夢簾廠衊蓋) = 壓艱遞壓範鑰淵憲膚積獵膚蓋願顧構艱獵鹽積 (範觸膚築餘憲衊憲餘窪 ) 更多	-	2023-12-09
CATS \| ML43257 (ESMO2023) 人工标引	N/A	小细胞肺癌一线	11	Atezolizumab+ carboplatin +etoposide (ACE)	選襯願壓選願構製餘築(繭鬱糧選廠簾鏇蓋鑰糧) = 艱鏇鏇選襯鹹鹽衊觸範鬱範憲遞廠憲鏇鏇壓鏇 (觸艱顧願願觸顧膚顧壓, 30.4 ~ 86.2) 更多	积极	2023-10-21